Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DBV Technologies is a late clinical-stage biopharmaceutical company that isadvancing VIASKIN peanut patch, a novel epicutaneous immunotherapy (EPIT) fortreatment of pediatric peanut allergy. The company has proforma cash position of ~$284MM, which is expected to provide runway into 2Q27, per the company. We continue to believe that DBVT is best-positioned to spearheadthe immunotherapy space in peanut allergy (& potentially beyond) and we anticipate swift uptake of VIASKIN peanut patch.

Bears say

DBV Technologies is facing potential risks and setbacks, with a negative outlook, for its Viaskin technology and pipeline programs such as Viaskin Milk and Eosinophilic Esophagitis. Though their 1Q26 OpEx were slightly above estimate, the company ended the quarter with $229M in cash, which may be sufficient to fund operations into 2Q27. However, there are still potential risks, delays, and need for capital in the markets that could impact their success and stock performance.

DBVT has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 5 analysts, DBVT has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.